Pharmacodynamic modeling of synergistic birinapant/paclitaxel interactions in pancreatic cancer cells
For most patients, pancreatic adenocarcinoma responds poorly to treatment, and novel therapeutic approaches are needed. Standard-of-care paclitaxel (PTX), combined with birinapant (BRP), a bivalent mimetic of ...
Source: BMC Cancer - Category: Cancer & Oncology Authors: Jin Niu, Xue Wang, Jun Qu, Donald E. Mager and Robert M. Straubinger Tags: Research article Source Type: research